Those with the lowest cognitive performance pre-TAVI appear to have the most to gain in terms of cognitive improvement post-TAVI. In conclusion, cognitive decline and cognitive improvement are experienced by approximately 7% to 19% of patients after TAVI, respectively. Two factors were associated with these cognitive outcomes: (1) using a cerebral embolic protection device was associated with decreased prevalence of cognitive decline up to 1-week post-TAVI (2) baseline cognitive impairment had a large association with post-TAVI cognitive improvement. Results: Our pooled analysis showed that insulin use was associated with poor composite development of COVID-19 OR 2.06 (95 CI 1.70 2.48), p 0.00001, I2 83, random-effect modelling, and its subgroup which comprised of risk of. For cognitive improvement, the prevalence from 1 to 6 months and ≥6 months after TAVI was estimated to be 19% and 11%, respectively. Statistical analysis was done using Review Manager 5.4 and Comprehensive Meta-Analysis version 3 software. When robust cognitive change definitions were employed, the pooled prevalence of incident cognitive impairment up to 1-, 1 to 6-, and ≥6-months post-TAVI was 7%, 14%, and 12%, respectively. A systematic review identified 15 articles appropriate for meta-analysis. We sought to pool estimates to identify the prevalence of cognitive decline and improvement after TAVI, as well as associated factors for these outcomes. However, previous systematic reviews and meta-analyses have missed these subgroups by assessing whole-group-averages for cognitive outcomes. Changes to cognition, both decline and improvement, are commonly reported after transcatheter aortic valve implantation (TAVI). Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States.